TearScience announced the addition of Edward J. Holland, MD, to its board of directors, according to a company news release. Dr. Holland was awarded the Life Achievement Honor Award at the 2012 American Academy of Ophthalmology annual meeting and has been listed in the “Best Doctors in America” on numerous occasions. He has written over 200 articles in peer-reviewed journals and has received worldwide recognition for his knowledge and expertise.
“Dr. Holland is a leader in the field of cornea and ocular surface health. As a respected expert, his guidance will help shape how we further the understanding of MGD among ECPs. This is the first time that Dr. Holland has joined a commercial board of directors and we are honored to have him advise us in creating greater value for eye care,” Joseph Boorady, CEO of TearScience, said in the news release.
Appreciation of the chronic, obstructive and progressive nature of MGD has increased in recent years as research has revealed the importance of meibomian gland health for overall ocular surface health. LipiScan and LipiView II improve the ability of ECPs to image and view meibomian gland structure with unmatched clarity.